Camille Potey

Camille Potey
University of Lille Nord de France · Pharmacology

PharmD, PhD

About

27
Publications
1,469
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
170
Citations
Additional affiliations
April 2015 - September 2017
University of British Columbia - Vancouver
Position
  • PostDoc Position
November 2010 - April 2015
Centre Hospitalier Régional Universitaire de Lille
Position
  • Medical Doctor
November 2010 - March 2015
University of Lille Nord de France
Position
  • PhD Student

Publications

Publications (27)
Article
Background: Although several case series have described nitrous oxide-associated neurological disorders, a comprehensive assessment of exposure characteristics (e.g., time to onset, level of exposure) in substance abusers has not been performed. The aim of this study was to describe the onset patterns of recreational use of nitrous oxide-induced n...
Article
Background: Alcohol and benzodiazepines are psychoactive substances frequently associated in voluntary drug intoxications that share common mechanisms of action, including facilitation of GABAergic transmission. Objective: To assess the separate and combined effects of ethanol and diazepam acute exposure on hippocampal metabolite levels, as well...
Article
Full-text available
Several observational studies have found a link between the long-term use of benzodiazepines and dementia, which remains controversial. Our study was designed to assess (i) whether the long-term use of benzodiazepines, at two different doses, has an irreversible effect on cognition, (ii) and whether there is an age-dependent effect. One hundred and...
Conference Paper
Introduction: Alcohol dependence is the most severe stage of alcohol misuse. In France, the GABA-B receptor agonist baclofen has been used since 2008 to treat alcohol dependence. However, both efficacy and safety aspects of baclofen remain unclear in this indication [1]. Material and methods: BACLOPHONE (NCT02596763) is a multicentric phone-based...
Article
Full-text available
It has been suggested that cerebral microhemorrhages (CMHs) could be involved in cognitive decline. However, little is known about the sex-dependency of this effect. Using a multimodal approach combining behavioral tests, in vivo imaging, biochemistry, and molecular biology, we studied the cortical and hippocampal impact of a CMH in male and female...
Article
Background and purposes: Cerebral microhaemorrhages (CMH) are associated with cognitive decline in humans. In rodents, CMHs induce cognitive impairment in male mice only along with sex-specific cortical and hippocampal modifications affecting neural, glial and vascular functions. Statins, prescribed in the context of cardiovascular risk factors, h...
Article
Background: Abiraterone and enzalutamide are recently-approved androgen deprivation therapies (ADTs) for metastatic prostate cancer, with unknown cardiac safety profiles. Abiraterone has a propensity to hypermineralocorticism on top of androgen deprivation, so might carry an additional risk for atrial tachyarrhythmia (AT) and heart failure (HF) co...
Article
Background Abiraterone and enzalutamide are recently approved androgen deprivation therapies (ADT) for metastatic prostate cancer. The cardiac safety profile for the two drugs is unknown. Methods Using French and World Health Organization (WHO) pharmacovigilance databases, we performed a disproportionality-analysis of suspected adverse-drug-reacti...
Article
Full-text available
Cerebral microbleeds (CMBs) could contribute to cognitive impairment in the general population and in patients with dementia. We designed a study to (i) develop a murine model of CMBs, (ii) assess whether CMBs affect cognition in this model and (iii) assess whether this model is sensitive to pharmacological modulation. Male C57Bl6/J mice were stere...
Chapter
Ischemic stroke is a major public health issue. To date there are very few therapeutic options available, stressing the need for new alternatives. N-methyl-d-aspartate (NMDA) receptors appear to be interesting candidates among stroke therapeutic targets. They exert major physiological functions related to synaptic plasticity and cell survival but t...
Article
Objective: To determine whether the ratio single chain (sc)/(sc + 2 chain [tc]) recombinant tissue plasminogen activator (rtPA) influences outcomes in patients with cerebral ischemia. Methods: We prospectively included consecutive patients treated with IV rtPA for cerebral ischemia in 13 stroke centers and determined the sc/(sc + tc) ratio in th...
Article
Statins appear to be interesting drug candidates for preventive neuroprotection in ischemic stroke, given the clinical and experimental data available. Their acute protective effect is yet still to be confirmed. Male C57Bl6/JRj mice were submitted to MCAO and treated acutely with atorvastatin (10-20mg/kg/d; 24 or 72 hours). Functional recovery (neu...
Article
Full-text available
L es 2 principales classes d'hypolipémiants, fibrates et statines, se distinguent par un mécanisme d'action pléiotrope, se traduisant par des effets pharmacologiques autres que leur impact sur le métabolisme lipidique (figure). Les fibrates, agonistes du récepteur nucléaire PPARα (Peroxisome proliferator-activated receptor alpha), sont, par exemple...
Article
Full-text available
Background Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the demonstration is not clearly established in human, the underlying molecular mechanism may be of interest for future therapeutic purpos...
Article
Ischemic stroke still is a heavy public health burden, as effective therapeutic means remain scarce. Atorvastatin (AT), widely used as a preventive treatment in the cardiovascular field, possesses pleiotropic effects that give it protective properties in stroke. The goals of this work were to assess and characterize the neuro- and vasculoprotective...
Article
There is now substantial data in the literature showing that statins can protect against cerebral ischemia. This neuroprotective potency is related to their pleiotropic effects that modulate various pathways implicated in the pathophysiology of stroke. It has been demonstrated that statins exert anti-inflammatory and vasculoprotective effects, thus...
Article
A medication-related cause must be sought when unusual symptoms occur. Topical treatments, including eye drops, whose side effects are more common in exposed children, need to be verified. We report here the cases of two children who developed systemic symptoms after the administration of atropine-based mydriatic eye drops. A 6-month-old boy was ad...
Article
Full-text available
Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it...
Article
A medication-related cause must be sought when unusual symptoms occur. Topical treatments, including eye drops, whose side effects are more common in exposed children, need to be verified. We report here the cases of two children who developed systemic symptoms after the administration of atropine-based mydriatic eye drops. A 6-month-old boy was ad...

Network

Cited By